A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Myasthenia Gravis

Interventions

DRUG: Remibrutinib (Blinded)
OTHER: Placebo
DRUG: Remibrutinib (Open Label)

Sponsor

Novartis Pharmaceuticals